Oppenheimer lowered the firm’s price target on Q32 Bio (QTTB) to $20 from $80 and keeps an Outperform rating on the shares.
The company announced top-line results from the SIGNAL-AA Phase IIa signal finding clinical trial evaluating bempikibart (ADX ...
Q32 Bio reports Phase 2a SIGNAL-AA trial results for bempikibart in alopecia areata, showing safety and modest efficacy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback